Joseph Petroziello
Keine laufenden Positionen mehr
Profil
Joseph Petroziello worked as the Head of Antigen Discovery at Seagen Inc. He was also the Head of Medical Writing and Scientific Communications at Juno Therapeutics, Inc. from 2014 to 2018.
From 2018 to 2020, he served as the VP of Scientific and Corporate Communications at Brainstorm Cell Therapeutics, Inc. Mr. Petroziello received his undergraduate and graduate degrees from the University of Scranton in 1992 and 1996, respectively.
Ehemalige bekannte Positionen von Joseph Petroziello
| Unternehmen | Position | Ende |
|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. | Public Communications Contact | 01.04.2020 |
| JUNO THERAPEUTICS INC | Corporate Officer/Principal | 01.01.2018 |
| SEAGEN INC. | Corporate Officer/Principal | - |
Ausbildung von Joseph Petroziello
| University of Scranton | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
